Budesonide + salbutamol

Articles · New Medicines ·
108622005

Articles

New Medicines

Moderate to severe asthma

Information

New formulation
AstraZeneca
AstraZeneca

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Inhaled corticosteroid and short acting bronchodilator, used when required. Each dose of PT027 delivers 160μg budesonide (ICS) and 180μg salbutamol.
5.4 million people in the UK receive treatment for asthma: 1 in 11 children and 1 in 12 adults. It is the most common chronic medical condition in children [1].
Moderate to severe asthma
Inhalation